Home › Compare › ABZPY vs ABBV
ABZPY yields 6.33% · ABBV yields 3.06%● Live data
📍 ABZPY pulled ahead of the other in Year 1
Combined, ABZPY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ABZPY + ABBV for your $10,000?
Aboitiz Power Corporation, through its subsidiaries, engages in the power generation, distribution, and retail electricity businesses in the Philippines. It operates hydropower, geothermal, solar, coal, and oil power plants. The company sells its electricity through power supply contracts, ancillary service procurement agreements, and trading in the wholesale electricity spot market. It also distributes electricity to the industrial, residential, commercial, and other customers; and provides electricity-related services, such as installation of electrical equipment through nine distribution utilities that supply electricity to franchise areas covering 18 cities and municipalities and five economic zones in Luzon, Visayas, and Mindanao. In addition, the company is involved in the retail of electricity to various industries, including property development, meat processing, semiconductors, steel, and cement. As of February 28, 2022, it owned 5,332 megawatts of net sellable capacity. The company was incorporated in 1998 and is headquartered in Taguig City, the Philippines. Aboitiz Power Corporation is a subsidiary of Aboitiz Equity Ventures, Inc.
Full ABZPY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.